Abstract
Aim:
Owing to its mysterious etiology, pathogenesis of preeclampsia (PE) remains controversial. Here we aimed to compare the levels of an angiogenesis marker, split and hairy related protein-1 (SHARP1), in PE vs. normal pregnancy.
Methods:
Thirty-one patients with early-onset PE (EOPE), 26 patients with late-onset PE (LOPE), and 33 patients as a control group were recruited for this study in a tertiary referral center in Ankara, Turkey. Maternal venous SHARP1 levels and individual characteristics of the three groups were compared.
Results:
Age and body mass indices were similar among the three groups. SHARP1 levels in patients with PE (27.7±13.2 ng/mL) were significantly lower than in the control group (34.7±17 ng/mL) (P=0.006). Additionally, SHARP1 levels were significantly different among patients in EOPE, LOPE, and control groups (P=0.022). Birth weights and Apgar scores in patients in EOPE group were significantly lower than the other two groups and showed a gradual increase from the EOPE group to the LOPE and the control group. Binary logistic regression method demonstrated that maternal venous SHARP1 level was a risk factor for PE.
Conclusions:
Maternal venous SHARP1 levels in PE are lower than a normal pregnancy. Its clinical applicability and role as a candidate for making sense of the distinctive pathogenesis of the EOPE and LOPE remain to be elucidated.
Author’s statement
Conflict of interest: Authors state no conflict of interest.
Material and methods: Informed consent: Informed consent has been obtained from all individuals included in this study.
Ethical approval: The research related to human subject use has complied with all the relevant national regulations, and institutional policies, and is in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.
References
[1] Lenfant C, National Education Program Working Group on High Blood Pressure in Pregnancy. Working group report on high blood pressure in pregnancy. J Clin Hypertens (Greenwich). 2001;3:75–88.10.1111/j.1524-6175.2001.00458.xSearch in Google Scholar
[2] Roberts JM, Gammil HS. Preeclampsia: recent insights. Hypertension. 2005;46:1243–9.1623051010.1161/01.HYP.0000188408.49896.c5Search in Google Scholar
[3] Stanczuk GA, Mccoy MJ, Hutchinson IV, Sibanda EN. The genetic predisposition to produce high levels of TGF-beta1 impacts on the severity of eclampsia/pre-eclampsia. Acta Obstet Gynecol Scand. 2007;86:903–8.10.1080/0001634070141694517653872Search in Google Scholar
[4] Laresgoiti-Servitje E, Gomez-Lopez N, Olson DM. An immunological insight into the origins of pre-eclampsia. Hum Reprod Update. 2010;16:510–24.10.1093/humupd/dmq00720388637Search in Google Scholar
[5] Shamshirsaz AA, Paidas M, Krikun G. Preeclampsia, hypoxia, thrombosis, and inflammation. J Pregnancy. 2012;2012:374047.2217502310.1155/2012/374047Search in Google Scholar
[6] Tal R. The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Biol Reprod. 2012;87:134.2303415610.1095/biolreprod.112.102723Search in Google Scholar
[7] Liu W, Wang SJ, Lin QD. Study on the expressions of PHD and HIF in placentas from normal pregnant women and patients with preeclampsia. Int J Biol Sci. 2014;10:278–84.10.7150/ijbs.637524644426Search in Google Scholar
[8] Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature. 2012;487:380–4.10.1038/nature1120722801492Search in Google Scholar
[9] Fujimoto K, Shen M, Noshiro M, Matsubara K, Shingu S, Honda K, et al. Molecular cloning and characterization of DEC2, a new member of basic helix-loop-helix proteins. Biochem Biophys Res Commun. 2001;280:164–71.1116249410.1006/bbrc.2000.4133Search in Google Scholar
[10] Rossner MJ, Oster H, Wichert SP, Reinecke L, Wehr MC, Reinecke J, et al. Disturbed clockwork resetting in Sharp-1 and Sharp-2 single and double mutant mice. PLoS One. 2008;3:e2762.10.1371/journal.pone.000276218648504Search in Google Scholar
[11] Baier PC, Brzózka MM, Shahmoradi A, Reinecke L, Kroos C, Wichert SP, et al. Mice lacking the circadian modulators SHARP1 and SHARP2 display altered sleep and mixed state endophenotypes of psychiatric disorders. PLoS One. 2014;9:e110310.2534047310.1371/journal.pone.0110310Search in Google Scholar
[12] Andraweera PH, Dekker GA, Roberts CT. The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update. 2012;18:436–57.2249525910.1093/humupd/dms011Search in Google Scholar
[13] Khodzhaeva ZS, Kogan YA, Shmakov RG, Klimenchenko NI, Akatyeva AS, Vavina OV, et al. Clinical and pathogenetic features of early- and late-onset pre-eclampsia. Matern Fetal Neonatal Med. 2016;29:2980–6.10.3109/14767058.2015.1111332Search in Google Scholar
[14] National High Blood Pressure Education Program Working Group. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1–22.10.1067/mob.2000.107928Search in Google Scholar
[15] Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631–44.10.1016/S0140-6736(10)60279-620598363Search in Google Scholar
[16] World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Med Assoc. 2013;310:2191–4.10.1001/jama.2013.281053Search in Google Scholar
[17] Osol G, Mandala M. Maternal uterine vascular remodeling during pregnancy. Physiology (Bethesda). 2009;24:58–71.1919665210.1152/physiol.00033.2008Search in Google Scholar
[18] Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am. 2010;37:239–53.10.1016/j.ogc.2010.02.01320685551Search in Google Scholar
[19] Rios DR, Alpoim PN, Godoi LC, Perucci LO, de Sousa LP, Gomes KB, et al. Increased Levels of sENG and sVCAM-1 and Decreased Levels of VEGF in Severe Preeclampsia. Am J Hypertens. 2016;29:1307–10.2647608310.1093/ajh/hpv170Search in Google Scholar
[20] Liao Y, Lu W, Che Q, Yang T, Qiu H, Zhang H, et al. SHARP1 suppresses angiogenesis of endometrial cancer by decreasing hypoxia-inducible factor-1α level. PLoS One. 2014;9:e99907.10.1371/journal.pone.009990724918449Search in Google Scholar
[21] Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature. 2012;487:380–4.10.1038/nature1120722801492Search in Google Scholar
[22] Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med. 2001;7:345–50.1151699410.1016/S1471-4914(01)02090-1Search in Google Scholar
[23] Sato F, Bhawal UK, Kawamoto T, Fujimoto K, Imaizumi T, Imanaka T, et al. Basic-helix-loop-helix (bHLH) transcription factor DEC2 negatively regulates vascular endothelial growth factor expression. Genes Cells. 2008;13:131–44.10.1111/j.1365-2443.2007.01153.x18233956Search in Google Scholar
[24] Gordon LK, Kiyohara M, Fu M, Braun J, Dhawan P, Chan A, et al. EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF. Oncogene. 2013;32:5369–76.2333433110.1038/onc.2012.622Search in Google Scholar
[25] Ashur-Fabian O, Yerushalmi GM, Mazaki-Tovi S, Steinberg DM, Goldshtein I, Yackobovitch-Gavan M, et al. Cell free expression of hif1α and p21 in maternal peripheral blood as a marker for preeclampsia and fetal growth restriction. PLoS One. 2012;7:e37273.10.1371/journal.pone.003727322615960Search in Google Scholar
[26] Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology. 2009;24:147–58.10.1152/physiol.00043.2008Search in Google Scholar
[27] Wu Y, Sato F, Bhawal UK, Kawamoto T, Fujimoto K, Noshiro M, et al. Basic helixloop-helix transcription factors DEC1 and DEC2 regulate the paclitaxel-induced apoptotic pathway of MCF-7 human breast cancer cells. Int J Mol Med. 2011;27:491–5.Search in Google Scholar
[28] Wu Y, Sato F, Bhawal UK, Kawamoto T, Fujimoto K, Noshiro M, et al. BHLH transcription factor DEC2 regulates pro-apoptotic factor Bim in human oral cancer HSC-3 cells. Biomed Res (Tokyo). 2012;33:75–82.10.2220/biomedres.33.75Search in Google Scholar
[29] van der Merwe JL, Hall DR, Wright C, Schubert P, Grové D. Are early and late preeclampsia distinct subclasses of the disease – what does the placenta reveal? Hypertens Pregnancy. 2010;29:457–67.10.3109/1064195090357228220701467Search in Google Scholar
[30] Wang L, Li X, Zhao Y, Fang C, Lian Y, Gou W, et al. Insights into the mechanism of CXCL12-mediated signaling in trophoblast functions and placental angiogenesis. Acta Biochim Biophys Sin (Shanghai). 2015;47:663–72.10.1093/abbs/gmv06426188201Search in Google Scholar
[31] Freitag N, Tirado-González I, Barrientos G, Herse F, Thijssen VL, Weedon-Fekjær SM, et al. Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proc Natl Acad Sci USA. 2013;110:11451–6.10.1073/pnas.1303707110Search in Google Scholar
[32] Liu H, Li Y, Zhang J, Rao M, Liang H, Liu G. The defect of both angiogenesis and lymphangiogenesis is involved in preeclampsia. See comment in PubMed Commons belowPlacenta. 2015;36:279–86.10.1016/j.placenta.2014.12.013Search in Google Scholar
[33] Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013;28:1–19.2339751410.1007/s10654-013-9762-6Search in Google Scholar
[34] Winnik S, Lohmann C, Siciliani G, von Lukowicz T, Kuschnerus K, Kraenkel N, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis – implications for cardiovascular safety. Int J Cardiol. 2013;168:2453–61.2356191710.1016/j.ijcard.2013.03.010Search in Google Scholar
©2017 Walter de Gruyter GmbH, Berlin/Boston